Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 09, 2021 4:25pm
126 Views
Post# 34216172

RE:RE:RE:RE:RE:Many new job postings

RE:RE:RE:RE:RE:Many new job postings Commercial banker in lifesci --so loans and services, not on the investment banking side. I do recall PL mentioning that he's spoken to a large group of JPM brokers on IR calls.  Maybe the wealth brokers told this banker to get to know THTX?  Pure speculation.  But it's always good to see any interest from a comemrcial or investment banker.  At least you have a contact that's interested in what you're doing.

qwerty22 wrote:

Anybody got any more thoughts on this? It doesn't get more scrappier than this scrap of info but it's intriguing.

 

jfm1330 wrote: On Linkedin, one of the person giving a thumb up to the poste about hiring at Thera is this guy

https://www.jpmorgan.com/commercial-banking/industries/life-sciences/chris-barrow

 

 

jfm1330 wrote: Thera is not running clinical trial in oncology by themselves. This is outsourced to a contract research organisation called PPD and the principal investigator, Dr. Funda Meric-Burnstam works for M.D. Anderson cancer center. Thera already has the personal needed to coordinate everything with the CRO. If they move to multiple phase II at the same time in the second half of 2022, they will hire more people, that's sure. But for now, I think they have enough people to handle the job on that front.

https://www.ppd.com/

https://clinicaltrials.gov/ct2/show/NCT04706962?term=theratechnologies&draw=2&rank=1


SPCEO1 wrote: The lack of clinical jobs being posted is something to think about. Should we assume a lot of partnerships are in TH's future where that work will be mostly done outside of TH and therefore there is no need for big staff additions there? Or, will we see a wave of scientific positions being filled after/if the phase 1a produces promising results?

 

 




<< Previous
Bullboard Posts
Next >>